Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation

Anne S Tsao; O Wolf Lindwasser; Alex A Adjei; Prasad S Adusumilli; Matthew L Beyers; Gideon M Blumenthal; Raphael Bueno; Bryan M Burt; Michele Carbone; Suzanne E Dahlberg; Marc de Perrot; Dean A Fennell; Joseph Friedberg; Ritu R Gill; Daniel R Gomez; David H Harpole Jr; Raffit Hassan; Mary Hesdorffer; Fred R Hirsch; Julija Hmeljak; Hedy L Kindler; Edward L Korn; Geoffrey Liu; Aaron S Mansfield; Anna K Nowak; Harvey I Pass; Tobias Peikert; Andreas Rimner; Bruce W S Robinson; Kenneth E Rosenzweig; Valerie W Rusch; Ravi Salgia; Boris Sepesi; Charles B Simone 2nd; Rajeshwari Sridhara; Peter Szlosarek; Emanuela Taioli; Ming-Sound Tsao; Haining Yang; Marjorie G Zauderer; Shakun M Malik

doi:10.1016/j.jtho.2018.08.2036

Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation

J Thorac Oncol. 2018 Nov;13(11):1655-1667. doi: 10.1016/j.jtho.2018.08.2036. Epub 2018 Sep 25.

Authors

Anne S Tsao¹, O Wolf Lindwasser², Alex A Adjei³, Prasad S Adusumilli⁴, Matthew L Beyers⁵, Gideon M Blumenthal⁶, Raphael Bueno⁷, Bryan M Burt⁸, Michele Carbone⁹, Suzanne E Dahlberg¹⁰, Marc de Perrot¹¹, Dean A Fennell¹², Joseph Friedberg¹³, Ritu R Gill¹⁴, Daniel R Gomez¹⁵, David H Harpole Jr¹⁶, Raffit Hassan¹⁷, Mary Hesdorffer¹⁸, Fred R Hirsch¹⁹, Julija Hmeljak²⁰, Hedy L Kindler²¹, Edward L Korn²², Geoffrey Liu²³, Aaron S Mansfield³, Anna K Nowak²⁴, Harvey I Pass²⁵, Tobias Peikert²⁶, Andreas Rimner²⁷, Bruce W S Robinson²⁸, Kenneth E Rosenzweig²⁹, Valerie W Rusch⁴, Ravi Salgia³⁰, Boris Sepesi³¹, Charles B Simone 2nd³², Rajeshwari Sridhara⁵, Peter Szlosarek³³, Emanuela Taioli³⁴, Ming-Sound Tsao³⁵, Haining Yang⁸, Marjorie G Zauderer³⁶, Shakun M Malik³⁷

Affiliations

¹ Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas.
² Coordinating Center for Clinical Trials, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
³ Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota.
⁴ Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
⁵ Emmes Corporation, Rockville, Maryland.
⁶ U.S. Food and Drug Administration, Silver Spring, Maryland.
⁷ Thoracic Surgery, Brigham and Women's Hospital, Boston, Massachusetts.
⁸ Department of Surgery, Division of Thoracic Surgery, Baylor College of Medicine, Houston, Texas.
⁹ University of Hawaii Cancer Center, Honolulu, Hawaii.
¹⁰ Department of Biostatistics, Dana Farber Cancer Institute, Boston, Massachusetts.
¹¹ Division of Thoracic Surgery, Toronto General Hospital, Toronto, Ontario, Canada; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
¹² Department of Genetics and Genome Biology, University of Leicester, Leicester, United Kingdom; University Hospitals of Leicester, Leicester, United Kingdom.
¹³ Department of Thoracic Surgery, University of Maryland Cancer Center, Baltimore, Maryland.
¹⁴ Department of Radiology, Brigham and Women's Hospital, Boston, Massachusetts.
¹⁵ Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas.
¹⁶ Division of Cardiothoracic Surgery, Department of Surgery, Duke University, Durham, North Carolina.
¹⁷ Thoracic and GI Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
¹⁸ Mesothelioma Applied Research Foundation, Alexandria, Virginia.
¹⁹ University of Colorado Cancer Center, IASLC, Denver, Colorado.
²⁰ The Company of Biologists, Cambridge, United Kingdom.
²¹ Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, Illinois.
²² Biometric Research Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
²³ Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
²⁴ Medical School, University of Western Australia, Perth, Western Australia, Australia; National Center for Asbestos Related Diseases, University of Western Australia, Perth, Western Australia, Australia.
²⁵ Department of Cardiothoracic Surgery, New York University, Langone Medical Center, New York, New York.
²⁶ Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota.
²⁷ Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
²⁸ National Centre for Asbestos Related Disease, University of Western Australia, Nedlands, Western Australia, Australia; Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.
²⁹ Department of Radiation Oncology, Mount Sinai Medical Center, New York, New York.
³⁰ Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, California.
³¹ Department of Thoracic and Cardiovascular Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, Texas.
³² Department of Radiation Oncology, University of Maryland Medical Center, Baltimore, Maryland.
³³ Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
³⁴ Epidemiology, Icahn School of Medicine at Mount Sinai, New York, New York; Department of Thoracic Surgery, Icahn School of Medicine at Mount Sinai, New York, New York.
³⁵ Department of Pathology, University of Toronto, Toronto, Ontario, Canada; Department of Pathology, Princess Margaret Cancer Centre/University Health Network, University of Toronto, Toronto, Ontario, Canada.
³⁶ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
³⁷ Clinical Investigations Branch, Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. Electronic address: shakun.malik@nih.gov.

PMID: 30266660
DOI: 10.1016/j.jtho.2018.08.2036

Abstract

On March 28- 29, 2017, the National Cancer Institute (NCI) Thoracic Malignacy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation convened the NCI-International Association for the Study of Lung Cancer- Mesothelioma Applied Research Foundation Mesothelioma Clinical Trials Planning Meeting in Bethesda, Maryland. The goal of the meeting was to bring together lead academicians, clinicians, scientists, and the U.S. Food and Drug Administration to focus on the development of clinical trials for patients in whom malignant pleural mesothelioma has been diagnosed. In light of the discovery of new cancer targets affecting the clinical development of novel agents and immunotherapies in malignant mesothelioma, the objective of this meeting was to assemble a consensus on at least two or three practice-changing multimodality clinical trials to be conducted through NCI's National Clinical Trials Network.

Keywords: Clinical trials; Malignant mesothelioma; Multimodality therapy; Pleural; Targeted therapy.

Publication types

Consensus Development Conference, NIH

MeSH terms

Consensus
Humans
Lung Neoplasms / pathology
Lung Neoplasms / therapy*
Mesothelioma / pathology
Mesothelioma / therapy*
Mesothelioma, Malignant
National Cancer Institute (U.S.)
United States